<PAGE>

================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

   [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
        ACT OF 1934

                For the quarterly period ended September 30, 2002

   [ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                 For the transition period from ______ to ______


                             LARK TECHNOLOGIES, INC.
        (Exact name of small business issuer as specified in its charter)


          DELAWARE                                            73-1461841
(State or other jurisdiction of                              (IRS Employer
Incorporation or organization)                            Identification No.)

                 9441 WEST SAM HOUSTON PARKWAY SOUTH, SUITE 103
                                HOUSTON, TX 77099
                    (Address of principal executive offices)

                                 (713) 779-3663
                           (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [X]  No [ ]

                APPLICABLE ONLY TO ISSUER INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes [ ]  No [ ]


                      APPLICABLE ONLY TO CORPORATE ISSUERS

As of September 30, 2002, there were 3,578,867 shares of Common Stock, par value
$0.001 per share, outstanding.

Transitional Small Business Disclosure Format (Check one): Yes [ ]  No [X]

================================================================================

<PAGE>

                             LARK TECHNOLOGIES, INC.

                              INDEX TO FORM 10-QSB
                    FOR THE QUARTER ENDED SEPTEMBER 30, 2002.


Part I   Financial Information (unaudited)
<TABLE>
<CAPTION>
                                                                                             Page
                                                                                             ----
<S>                                                                                          <C>
       Item 1.    Financial Statements

                      Balance Sheet.......................................................... 1

                      Statements of Operations............................................... 2

                      Statements of Cash Flows............................................... 3

                      Notes to Financial Statements.......................................... 4

       Item 2.    Management's Discussion and Analysis of
                  Financial Condition and Results of Operations.............................. 7

Part II  Other Information................................................................... 10

       Item 1.    Legal Proceedings.......................................................... 10

       Item 2.    Changes in Securities...................................................... 10

       Item 3.    Defaults upon Senior Securities............................................ 10

       Item 4.    Submission of Matters to a Vote of Security Holders........................ 10

       Item 5.    Other Information.......................................................... 11

       Item 6.    Exhibits and Reports on Form 8-K........................................... 11

Signatures................................................................................... 12

Certifications............................................................................... 13
</TABLE>

                                       i

<PAGE>


                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS
                             LARK TECHNOLOGIES, INC.
                                  BALANCE SHEET

<TABLE>
<CAPTION>
                                                                                         September 30, 2002
                                                                                       ----------------------
                                                                                            (Unaudited)
<S>                                                                                    <C>
ASSETS
Current assets
               Cash and cash equivalents                                                             $549,591
               Accounts receivable (net)                                                           $1,092,533
               Due from related parties                                                               $34,175
               Raw Materials                                                                          $43,128
               Work-in-process                                                                        $47,090
               Prepaid expenses                                                                      $182,022
                                                                                       ----------------------
Total current assets                                                                               $1,948,539

Property and equipment, net                                                                         1,937,902
Other assets, net                                                                                      13,641
                                                                                       ----------------------
Total assets                                                                                       $3,900,082
                                                                                       ======================

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
               Accounts payable                                                                      $379,591
               Capital lease obligations-current portion                                             $434,127
               Accrued expenses                                                                      $157,061
               Customer deposits                                                                     $361,622
                                                                                       ----------------------
Total current liabilities                                                                          $1,332,401

Capital lease obligations-long term portion                                                           801,367
Deferred rent expense                                                                                  34,857
                                                                                       ----------------------
Total Liabilities                                                                                   2,168,625

Stockholders' equity
               Preferred stock, $0.001 par value
                    Authorized shares - 2,000,000
                    None issued and outstanding
               Common stock, $0.001 par value
                    Authorized shares - 8,000,000
                    Issued shares: 3,583,898 and outstanding shares: 3,578,867                          3,584
               Additional paid-in capital                                                           2,691,856
               Treasury stock at cost                                                                  (6,865)
               Deferred compensation                                                                   (5,950)
               Accumulated comprehensive loss                                                          (5,994)
               Accumulated deficit                                                                   (945,174)
                                                                                       ----------------------
Total stockholders' equity                                                                          1,731,457
                                                                                       ----------------------
Total liabilities and stockholders' equity                                                          3,900,082
                                                                                       ======================
</TABLE>

See accompanying notes to the financial statements.

                                       1

<PAGE>

                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF OPERATIONS



<TABLE>
<CAPTION>
                                                 Three months Ended September 30,              Nine months Ended September 30,
                                             ----------------------------------------      ---------------------------------------
                                                    2001                   2002                   2001                  2002
                                             -----------------      -----------------      -----------------     -----------------
                                                            (Unaudited)                                   (Unaudited)
<S>                                          <C>                    <C>                    <C>                   <C>
Revenue:
        Laboratory services                         $1,279,563             $1,571,620             $4,359,355            $4,963,686

Costs and expenses:
        Costs of services                              792,652                814,781              3,104,135             2,600,517
        Sales, general and administrative              514,884                594,452              1,586,954             1,644,473
                                             -----------------      -----------------      -----------------     -----------------
Total costs and expenses                             1,307,536              1,409,233              4,691,089             4,244,990
                                             -----------------      -----------------      -----------------     -----------------
Operating income (loss)                                (27,973)               162,387               (331,734)              718,696

Other income and (expense):
        Interest expense                               (22,660)                (9,772)               (51,430)              (43,101)
        Interest income                                  3,288                  1,092                 17,684                 3,832
        Other income                                         0                      0                125,323                     0
                                             -----------------      -----------------      -----------------     -----------------
Total other income (expense)                           (19,372)                (8,680)                91,577               (39,269)
                                             -----------------      -----------------      -----------------     -----------------
Income (loss) before income taxes                      (47,345)               153,707               (240,157)              679,427

Provision for income taxes                                   0                      0                      0                32,000
                                             -----------------      -----------------      -----------------     -----------------
Net income (loss)                                     ($47,345)              $153,707              ($240,157)             $647,427
                                             =================      =================      =================     =================

Basic and diluted earnings (loss)
        per common share                                ($0.01)                 $0.04                 ($0.07)                $0.18
                                             =================      =================      =================     =================
</TABLE>

See accompanying notes to the financial statements.


                                       2
<PAGE>


                         PART I - FINANCIAL INFORMATION
                          ITEM 1. FINANCIAL STATEMENTS

                             LARK TECHNOLOGIES, INC.
                            STATEMENTS OF CASH FLOWS


<TABLE>
<CAPTION>
                                                                             Nine months ended
                                                                               September 30,
                                                                    -----------------------------------
                                                                         2001                 2002
                                                                    --------------       --------------
                                                                                (Unaudited)
<S>                                                                 <C>                  <C>
OPERATING ACTIVITIES
Net income (loss)                                                        ($240,157)             647,427
Adjustments to reconcile net loss
   to net cash provided by (used in) operating activities
               Depreciation and amortization                               324,171              331,318
               Provision for bad debts                                      13,647               16,169
               Changes in operating assets and liabilities:
                    Accounts receivable                                    137,186               (7,333)
                    Inventory                                              138,562               (5,378)
                    Prepaid expenses                                        28,629              (51,873)
                    Due to/from related parties                            (20,245)             (40,044)
                    Accounts payable                                       (88,223)              30,607
                    Accrued expenses                                        66,582                9,355
                    Deferred rent                                                -                6,993
                    Deposits                                              (649,194)               5,462
                                                                    --------------       --------------
Net cash provided by (used in) operating activities                       (289,042)             942,703

INVESTING ACTIVITIES
Purchases of property and equipment                                        (83,315)            (208,252)
                                                                    --------------       --------------
Net cash used in investing activities                                      (83,315)            (208,252)

FINANCING ACTIVITIES
Proceeds from issuance of notes payable                                     92,000                    -
Principal payments on notes payable                                       (106,054)            (420,929)
Principal payments on capital leases                                       (88,543)            (191,897)
Proceeds from exercised stock options                                          730               15,625
Cost to repurchase Treasury stock                                                -               (1,919)
                                                                    --------------       --------------
Net cash used by financing activities                                     (101,867)            (599,120)
Effect of currancy translation on cash                                           -                   18
                                                                    --------------       --------------
Net decrease in cash and cash equivalents                                 (474,224)             135,349
Cash and cash equivalents at beginning of period                           993,324              414,242
                                                                    --------------       --------------
Cash and cash equivalents at end of period                                 519,100              549,591
                                                                    ==============       ==============
</TABLE>

See accompanying notes to the financial statements.


                                       3
<PAGE>

                             LARK TECHNOLOGIES, INC.
                          NOTES TO FINANCIAL STATEMENTS
                                   (UNAUDITED)


1.       ORGANIZATION

         Lark Technologies, Inc., a Delaware corporation (the "Company" or
"Lark"), was formed on November 16, 1994, as a wholly-owned subsidiary of
SuperCorp Inc. ("SuperCorp"), for the purpose of merging with Lark Sequencing
Technologies, Inc., a Delaware corporation ("Sequencing"), as outlined in a
merger agreement ("Merger Agreement") entered into by SuperCorp and Sequencing
on October 28, 1994. SuperCorp approved the Merger Agreement on September 5,
1995 and by the stockholders of Sequencing on September 12, 1995. Because of the
merger, all of the shares of common and preferred stock of Sequencing were
exchanged for 1,800,000 shares of Common Stock of the Company with a par value
of $0.001 per share, and the 200,000 shares of Common Stock of the Company held
by SuperCorp were distributed to the shareholders of SuperCorp. The Company has
succeeded to all of the business previously undertaken by Sequencing. Lark
provides specialized laboratory services for DNA sequencing to biotechnology
researchers.

2.       ACCOUNTING POLICIES

Basis of Presentation

         The accompanying unaudited interim financial statements have been
prepared pursuant to the rules and regulations of the Securities and Exchange
Commission. Certain information in footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to these rules and
regulations. The accompanying unaudited interim financial statements reflect all
adjustments which the Company considers necessary for a fair presentation of the
results of operations for the interim periods covered and for the financial
condition of the Company at the date of the interim balance sheet. All such
adjustments are of a recurring nature. Results for the interim periods are not
necessarily indicative of results for the year.

         For financial reporting purposes, the merger of the Company and
Sequencing has been accounted for as a recapitalization of Sequencing, and the
historical financial statements of Sequencing prior to the merger became the
financial statements of the Company.

Recently Issued Accounting Standards

            In August 2001, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards ("SFAS") No. 144, "Accounting for
the Impairment or Disposal of Long-Lived Assets". SFAS No. 144 supercedes SFAS
No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to be Disposed of". SFAS No. 144 establishes a single accounting model
for long-lived assets to be disposed of by sale and requires that those
long-lived assets be measured at the lower of carrying amount or fair value less
cost to sell. The Company adopted this standard in the quarter ended March 31,
2002. The adoption had no impact on the Company's financial position or results
of operations.

3.       INVENTORY

         Raw materials inventory includes the direct costs of reagents
associated with sequencing reactions. At September 30, 2002 raw materials
inventory was $43,128.

         Work in process inventory includes the direct and indirect costs
associated with projects that were started but not yet completed at September
30, 2002. Direct costs include such items as the cost of labor, reagents and
supplies directly associated with each project. Indirect costs include such
items as general supplies, laboratory management, depreciation, and costs to
operate the lab. These costs are applied to each project on the basis of direct
labor hours incurred for the project, up to the point of measurement, such as
the end of an accounting period. At September 30, 2002, work in process
inventory was $47,090.

                                       4

<PAGE>


4.       NOTES PAYABLE

         On February 28, 2002, the Company renewed its revolving line of credit
and extended the maturity to December 31, 2002. Under the terms of its revolving
line, the Company may borrow up to $600,000 at the bank's prime rate plus 1.5%.
The borrowing base of this line of credit is equal to 80% of certain accounts
receivable that are no more than 90 days old. On September 30, 2002 the Company
had no outstanding balance under this line. Under the terms of the revolving
line of credit agreement, the Company is required to maintain certain financial
ratios and a specific level of net worth. As of September 30, 2002, the Company
was in compliance with these required financial ratios.

         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, 2001 the company
borrowed $92,000 under this facility. On that same day, the advance line feature
of this loan converted to a fixed facility requiring monthly payments over a 36
month period at the bank's prime rate plus 1.5%. The Company paid off this
facility during the quarter ended September 30, 2002.

5.       EARNINGS PER SHARE

         The following table sets forth the weighted average shares outstanding
for the computation of basic and diluted earnings per share:

<TABLE>
<CAPTION>
                                                 For the three months ending            For the nine months ending
                                                       September 30,                          September 30,
                                                    2001              2002                 2001              2002
                                                 ---------         ---------            ---------         ---------
<S>                                              <C>               <C>                  <C>               <C>
Weighted average common shares outstanding:      3,516,895         3,579,224            3,516,752         3,547,838
Dilutive securities - employee stock options:       63,420            33,530              105,381            91,256
                                                 ---------         ---------            ---------         ---------
Weighted average common shares outstanding
 Assuming full dilution:                         3,580,315         3,612,754            3,622,583         3,639,094
                                                 =========         =========            =========         =========
</TABLE>

         Options to purchase 454,440 and 668,440 shares of common stock were
outstanding during 2001 and 2002 respectively, but were not included in the
computation of diluted earnings per share because the effect would be
antidilutive.

6.       COMMITMENTS AND CONTINGENCIES

         The Company is involved in various legal proceedings that have arisen
in the ordinary course of business. In the opinion of management, based on
consultations with counsel and a review of the facts, the ultimate liability to
the Company will not have a material effect on the financial position of the
Company.

Stock Options

         On May 29, 2002, the Board of Directors adopted the Lark Technologies,
Inc. 2002 Stock Option Plan ("2002 Plan") covering 1,000,000 shares of its
Common Stock. Subsequently, it was determined that the Company's 2000 Stock
Option Plan ("2000 Plan") had expired by its terms on May 10, 2001, and that
approximately 866,440 options granted under the 2000 Plan had either expired
effective that day or were void. On July 16, 2002, the Board authorized the
issuance of 95,000 non-qualified stock options to employees who held options
under the 2000 Plan on the same terms under the 2002 Plan, and the issuance of
769,444 non-qualified options to directors. Also, effective July 16, 2002, the
number of shares covered by the 2002 Plan was increased to 2,000,000. Certain of
the issuances under the 2002 Plan were at exercise prices that were less than
fair market value and resulted in approximately $6,000 of deferred compensation
in the current quarter. The deferred compensation expense will be amortized into
compensation expense over the vesting period of approximately four years. The
2002 Plan provides for the granting of non-qualified stock options without the
approval of the Company's stockholders. To grant qualified stock options, the
2002 Plan required approval by the Company's stockholders within one year of the
effective date of the 2002 Plan. The 2002 Plan was voted upon and approved at
the Company's annual stockholders' meeting on August 30, 2002.

                                       5
<PAGE>

Operating Leases

         The Company leases certain real estate for its corporate office in
Houston, Texas and branch office in the United Kingdom, as well as certain
equipment under non-cancelable lease agreements, which expire at various dates.
In late January 2000, the Company moved into its new corporate headquarters and
lab facility. This new facility provides the Company with approximately 15,000
square feet for a period of 10 years. Total rent expense for all operating
leases for the quarter ended September 30, 2001 and 2002 was $55,749 and
$98,176, respectively.

         Future minimum payments under these operating leases are as follows:

<TABLE>
<S>                                                           <C>
                  2002                                       $   67,320
                  2003                                          177,188
                  2004                                          161,825
                  2005                                          169,313
                  2006                                          155,769
                  Thereafter                                    467,307
                                                             ----------
                                                             $1,198,722
                                                             ==========
</TABLE>

Capital Leases

         On September 20, 2002, the Company entered into a capital lease for the
purchase of a new automated DNA sequencer for the UK lab. Under the terms of the
36 months lease, the Company may purchase this equipment for a nominal amount at
the end of the lease.

         On September 27, 2002, the Company entered into a capital lease for the
purchase of two new automated DNA sequencers for the US lab. Under the terms of
the 36 months lease, the Company may purchase this equipment for a price below
fair market value at the end of the lease.

         The gross amount of assets recorded under capital leases at September
30, 2002 was $1,480,449. The related accumulated amortization was $137,043 at
September 30, 2002. Under the terms of the capital leases, the Company is
obligated to make payments as set forth in the table below and, subject to
certain conditions, may purchase the equipment at the end of the lease for a
nominal amount.

         Future minimum payments under these capital leases are as follows:

<TABLE>
<S>                                                           <C>
                  2002                                       $  129,412
                  2003                                          509,363
                  2004                                          415,770
                  2005                                          308,391
                  2006                                            8,396
                                                             ----------
                                                             $1,371,332

         Less interest portion of payments                      135,838

         Net present value of lease payments                  1,235,494

         Less current portion                                   434,127
                                                             ----------
         Capital lease obligation less current portion       $  801,367
                                                             ==========
</TABLE>

         Amortization of capital lease assets is included in depreciation
expense.

Patent License Agreement

         Effective June 15, 1995, the Company entered into an exclusive patent
sub-license agreement with another biotech company. The agreement grants to the
Company an exclusive license to certain "Licensed Patent Rights" of this third
party and requires the Company to perform research and development efforts as
defined in the agreement.

                                       6

<PAGE>

The Company is required to pay the third party a royalty of 25% to 50% of all
consideration the Company receives as a result of sales of licensed products and
licensed processes or a sub-license or assignment of the Company's rights under
the agreement. If the Company does not meet the research and development
milestones as defined in the agreement, or is unable to successfully
commercialize the results of the research and development efforts, the agreement
will terminate. Otherwise, the agreement will terminate upon the dissolution of
the Company or the expiration of the "Licensed Patent Rights". The Company may
also terminate the agreement with 60 days written notice to the third party.

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
         OF OPERATIONS

The following discussion and analysis should be read in conjunction with the
Financial Statements and the accompanying Notes herein, and is qualified
entirely by the foregoing and by other more detailed financial information
appearing elsewhere.

BUSINESS OF LARK
Lark is a leader in providing contract molecular biology services to the
pharmaceutical, biotechnology and agbio industries. Lark's services are used
worldwide by research organizations and drug development institutions to
accelerate their efforts in bringing products to the market. Lark's contract
research service portfolio consists of over a hundred different molecular
biology services in the areas of Nucleic Acid Extraction Services, DNA
Sequencing Services, Genetic Stability Testing Services, Gene Expression and
Detection Services, and Custom Molecular Biology Services. A highly trained and
educated scientific staff working in a facility that is compliant with the Food
and Drug Administration's ("FDA") Good Laboratory Practices ("GLP") (CFR Title
21, Part 58) performs all of these services.

CUSTOM DNA SEQUENCING SERVICES
The foundation of the company is based upon a broad breadth of DNA sequencing
services. Approximately 75% of projects currently booked by the Company are for
Custom DNA Sequencing Services. The Company has extensive expertise in DNA
sequencing and has incorporated multiple sequencing technologies into its
laboratory to accommodate both high throughput and highly complex projects.
Depending upon the nature of a project, Lark will develop an optimal sequencing
strategy to generate consistent, high quality sequence data for use in
applications spanning basic research to FDA submissions.

GENETIC STABILITY TESTING ("GST") SERVICES
Lark introduced genetic stability testing as a product offering in 1996 to
assist clients in meeting the regulatory guidelines established for development
and maintenance of specific genetically engineered biotechnology products. Lark
analyzes and provides a comprehensive report on the genetic integrity of cell
banks used to produce recombinant proteins, monoclonal antibodies, gene therapy,
and vaccine products, which is essential to creating a reliable process,
producing a pure biologic product in high yield. The Company believes the need
for these services is growing rapidly with the number of biotechnology products
entering the clinical development pipeline. The FDA is requiring this work be
performed according to GLP guidelines, a key differentiating feature of Lark's
services. True GLP guidelines are not commonly followed in research laboratories
and many service laboratories due to the rigorous demands of documentation and
adhesion to the quality assurance regulations. Lark's entire laboratory operates
according to GLPs but it is particularly important for performing the genetic
stability testing services.

GENETICALLY MODIFIED ORGANISM ("GMO") TESTING SERVICES
Lark provides services for identification and characterization of genetically
modified ("GM") crops and plants. Several effective services have been developed
for genetic testing of food and agricultural products. These laboratory services
offer a broad range of genetics-based assays for qualitative and quantitative
analysis of biotech modifications in plants such as corn, soy and other grain
products. Companies are requiring GMO testing of ingredients for labeling
requirements and to ensure the presence or absence of genetically enhanced
characteristics. This area clearly has the potential for tremendous growth as a
result of the increasing pressures to label and certify all agricultural
products.

GENE EXPRESSION AND DETECTION SERVICES
The genomics initiative continues to provide an abundance of gene sequence
information albeit little information regarding the function of genes in their
biochemical pathways. Lark continues to identify services it can offer to assist
clients in ascertaining the biological role of a gene by determining if, when,
and at what level a gene is being


                                       7
<PAGE>

expressed in any number of samples of interest. These services can be important
in identifying novel genes, confirming the validity of a gene as a drug target,
and monitoring a target gene through the product development process. These
services are highly complementary to genomic research and will continue to be of
growing importance to companies applying genomics to their product development
efforts. Lark will continue to expand the number of services it offers for gene
expression and detection purposes by actively seeking technologies, which meet
the growing needs of its client base.

CUSTOM CORE MOLECULAR BIOLOGY SERVICES
Many of the custom projects Lark performs require the application of molecular
biology techniques either upstream or downstream from the main service provided.
As a result, Lark has developed the ability to perform a breadth of molecular
biology techniques, which can be offered as a complement to another service, or
as a stand-alone service. The Company envisions an expanding list of custom
services as new technologies and advances occur in the field of molecular
biology.

In 1995 Lark undertook a senescence gene discovery program for its own account.
Although several genes were discovered in this program, lack of gene
functionality coupled with license issues caused Lark to reduce its funding for
this program. Lark continues to work towards license issue resolution and
eventual potential sublicense agreements.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company's discussion and analysis of its financial condition and results of
operations are based upon its financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States.
The preparation of these financial statements requires the Company to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and
liabilities. On an on-going basis, the Company evaluates these estimates,
including those related to customer bad debts, estimated useful lives of
property and equipment, and income taxes. The Company bases its estimates on
historical experience and on various other assumptions that are believed to be
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying values of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these
estimates.

The Company believes the following critical accounting policies reflect the more
significant judgments and estimates used in the preparation of the financial
statements:

ALLOWANCE FOR DOUBTFUL ACCOUNTS--The Company maintains an allowance for doubtful
accounts for estimated losses resulting from the inability of our customers to
pay for laboratory service fees. The Company generally requires a deposit of
approximately 50% of the total anticipated billings prior to commencing work on
larger laboratory service projects. Historically, the Company has not
experienced significant bad debts. However, if the financial condition of the
Company's customers were to deteriorate rapidly, resulting in nonpayment, the
Company could be required to provide additional allowances for doubtful accounts
which would decrease net income in the period that this determination was made.

PROPERTY AND EQUIPMENT--Property and equipment relate primarily to laboratory
equipment and computer equipment. These costs are depreciated or amortized over
the estimated useful lives of the assets. If technology related to the
laboratory equipment or computer equipment was to rapidly change, the estimated
useful lives of existing equipment may be shortened. This would result in
accelerating depreciation and amortization expense, which would decrease net
income in the periods following such a determination. Additionally, effective
January 1, 2002, the Company periodically evaluates the costs of property and
equipment for impairment in accordance with Statement of Accounting Standards
No. 144, "Accounting for Impairment or Disposal of Long-Lived Assets." If events
or circumstances were to indicate that any of the long-lived assets might be
impaired, the Company would be required to analyze the estimated undiscounted
future cash flows from the applicable assets. If the carrying value of the asset
were less than the undiscounted cash flows, the Company would be required to
record an impairment loss, which would reduce net income, to the extent that the
carrying value of the asset exceeded fair value.

DEFERRED TAXES--The Company has recorded a valuation allowance to reduce net
deferred tax assets to zero as a result of the Company's cumulative loss
position and the uncertainty of the Company's ability to realize the net
deferred tax assets in the future. If the Company were able to realize the
deferred tax assets in the future, an adjustment to reduce the valuation
allowance would increase net income.

                                       8

<PAGE>

RESULTS OF OPERATIONS

         GROSS REVENUES. Gross revenues increased 23% from $1,279,563 to
$1,571,620 for the three-month periods ended September 30, 2001 and 2002,
respectively. Gross revenues increased 14% from $4,359,355 to $4,963,686 for the
nine-month periods ended September 30, 2001 and 2002 respectively. The increase
in revenues for the quarter was the result of increased sales of our core
sequencing and genetic stability testing services.

         COSTS OF SERVICES. Costs of services consist primarily of labor and
laboratory supplies. Costs of services increased 3% from $792,652 to $814,781
for the three-month periods ended September 30, 2001 and 2002, respectively.
Costs of services decreased 16% from $3,104,135 to $2,600,517 for the nine-month
periods ended September 30, 2001 and 2002, respectively. The decrease for the
quarter was a result of our continued focus on cost containment and increasing
efficiencies. Costs of services as a percentage of revenue were 62% and 52% for
the three-month periods ending September 30, 2001 and 2002 respectively and 71%
and 52% for the nine-month periods ended September 30, 2001 and 2002,
respectively.

         SALES, GENERAL AND ADMINISTRATIVE EXPENSES. Sales, general and
administrative expenses consist primarily of salaries and related costs,
depreciation, amortization, legal and professional costs, rent, travel, and
advertising. Sales, general and administrative expenses increased 15% from
$514,884 to $594,452 for the three-month periods ended September 30, 2001 and
2002, respectively. The increase resulted mainly from recruiting and relocation
expenses associated with hiring new territory representatives. Sales, general
and administrative expenses increased 4% from $1,586,954 to $1,644,473 for the
nine-month period ended September 30, 2001 and 2002, respectively. Sales,
general and administrative expenses as a percentage of revenue were 40% and 38%
for the three-month and 36% and 33% for the nine-month periods ended September
30, 2001 and 2002, respectively.

         VARIABILITY OF FUTURE OPERATING RESULTS. The growth in quarterly
revenues was largely attributable to increased sales in sequencing services.
Although the Company expects higher and less variable revenue streams resulting
from the implementation of our business strategies, the ultimate success of
these changes cannot be reasonably predicted.

         LIQUIDITY AND CAPITAL RESOURCES. Operating cash flow was ($289,042) and
$942,703 for the nine-month periods ended September 30, 2001 and 2002,
respectively. The positive operating cash flow for the period ending September
30, 2002 occurred mainly as a result of net income of $647,427.

         On February 28, 2002, the Company renewed its revolving loan facility
through December 31, 2002, and may continue to borrow up to $600,000 under the
terms of the credit line. As of September 30, 2002, there were no amounts
outstanding on this line and the Company was in compliance with all of the
required financial ratios for this facility.

         During January 2001, the company arranged an advance term loan facility
to finance the purchase of various pieces of lab equipment with the same bank
that provided the revolving line of credit. On February 26, 2001, the company
borrowed $92,000 under this facility. On that same day, the advance line feature
of this loan converted to a fixed facility requiring monthly payments over a 36
month period at the bank's prime rate plus 1.5%. As of September 30, 2002, the
Company has repaid this loan early.

         CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENT--The following table
summarizes the Company's contractual obligations and commercial commitments as
of September 30, 2002 and the effect they are expected to have on its liquidity
and capital resources:

<Table>
<Caption>
Contractual                                                      Less than                              After
Obligations                                      Total             1 Year          1-3 Years           3 Years
---------------------------------------      -------------     -------------    ---------------     -------------
<S>                                          <C>               <C>              <C>                 <C>
Revolving line of credit                     $           -     $           -    $             -     $           -
Other credit facilities                                  -                 -                  -                 -
Capital lease obligations                        1,371,332           511,434            846,464            13,434
Non-cancelable operating leases                  1,198,722           204,051            286,938           707,733
                                             -------------     -------------    ---------------     -------------
Total contractual obligations                $   2,570,054     $     715,485    $     1,133,402     $     721,167
                                             =============     =============    ===============     =============
Other commercial commitments:
Revolving line of credit availability        $     583,277     $     583,277    $             -     $           -
                                             =============     =============    ===============     =============
</Table>

                                       9

<PAGE>

         MATERIAL COMMITMENTS. The Company currently has no outstanding
material commitments.

         As of September 30, 2002, an evaluation was performed under the
supervision and with the participation of the Company's management, including
the CEO and CFO, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures. Based on that evaluation, the
Company's management, including the CEO and CFO, concluded that the Company's
disclosure controls and procedures were effective as of September 30, 2002.
There have been no significant changes in the Company's internal controls or in
other factors that could significantly affect internal controls subsequent to
September 30, 2002.

                           PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

         On June 29, 2000 Joel S. Kanter sued the Company in U.S. District Court
for the Southern District of Texas, Houston Division. The Company entered into a
letter of intent with the "Kanter Group" in 1999 providing for Mr. Kanter to
conduct, or invest in, a proposed $1,320,000 private offering of Company stock.
The transaction was not completed by the time specified in the letter of intent
(on or before November 1, 1999) and Mr. Kanter and the Company continued to work
on the offering for a time thereafter. Mr. Kanter alleges the Company did not
allow him to complete the offering and seeks damages for the breach of the
letter of intent and for reliance damages for his expenses following expiration
of the letter of intent. The Company's position is that there was no binding
agreement, that the letter of intent, by its own terms, prevents Kanter from
recovering and that Kanter imposed material conditions to the completion of the
transaction which were not set forth in the letter of intent. The Company filed
a motion for summary judgment in the case, which the court granted and based
upon which the court entered a final judgment on September 16, 2002 dismissing
all of Kanter's claims. Kanter has filed an appeal of that ruling to the United
States Court of Appeals for the Fifth Circuit. The Company intends to vigorously
defend the appeal and Management believes that it is without merit.

ITEM 2.  CHANGES IN SECURITIES

         In the third quarter of 2002, the Company repurchased the following
number of shares of its Common Stock on the dates indicated below, all pursuant
to the tender offer to purchase odd lot shares of outstanding Company common
stock:

<TABLE>
<CAPTION>
          Date       Shareholder                                   No. of Shares
         -------     -----------                                   -------------
<S>                                                                <C>
         8/20/02     25 odd lots                                        -268
         9/11/02     13 odd lots                                        -263
</TABLE>

No underwriter was used in the repurchase. The aggregate price paid for the odd
lots was $1,919, representing an average price of $3.61 per share for the common
stock repurchased in the third quarter.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

         Not applicable.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         At the Annual Meeting of Shareholders of Lark Technologies, Inc. held
on August 30, 2002, the shareholders elected the directors named, and approved
the matters described, in the proxy statement for the meeting. The number of
votes cast for, against or withheld, as well as the number of abstentions and
broker non-votes, on each matter voted on at the meeting and each nominee for
office were as follows:

<TABLE>
<CAPTION>
         Matter Voted On:                                              WITHHELD OR            ABSTAIN AND
                                                        FOR              AGAINST               NON-VOTES
                                                        ---              -------               ---------
<S>                                                  <C>               <C>                    <C>
         1.  Election of directors:
                  George M. Britton                  3,122,570             1,414                 214,698
                  David A. Lawson                    3,122,580             1,404                 214,698
                  E.J. (Jere) Pederson               3,122,580             1,404                 214,698
                  Carl W. Balezentis, Ph.D.          3,122,532           102,904                 113,246
</TABLE>

                                       10
<PAGE>

<TABLE>
<CAPTION>
         Matter Voted On:                                              WITHHELD OR            ABSTAIN AND
                                                        FOR              AGAINST               NON-VOTES
                                                        ---              -------               ---------
<S>                                                  <C>               <C>                    <C>
         2.  Approval of Lark Technologies,
             Inc. 2002 Stock Option Plan.            1,482,810           428,859               1,427,013

         3.  Ratification of Ernst &Young LLP
             as Company's independent public
             accountants.                            3,246,197             3,888                  88,597
</TABLE>

ITEM 5.  OTHER INFORMATION

         Not applicable.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         No reports on Form 8-K were filed during the quarter ending September
30, 2002.

Index of Exhibits

           2.1(1)   The Agreement of Merger of November 18, 1994, between Lark
                    Technologies, Inc. and Lark Sequencing Technologies, Inc.
                    providing for the merger of Lark Sequencing Technologies,
                    Inc. into the Company.

           3.1(1)   Bylaws of Lark Technologies, Inc., as amended.

           3.2(1)   The Certificate of Incorporation of Lark Technologies, Inc.,
                    as amended.

           4.1(2)   Lark Technologies, Inc. 2000 Stock Option Plan adopted by
                    the Company.

           4.2(3)   Lark Technologies, Inc. 2002 Stock Option Plan adopted by
                    the Company.


(1) Incorporated by reference from the Company's Registration Statement on Form
S-4 dated August 14, 1995, Commission File No. 33-90424. The exhibit numbering
system used in Form S-4 differed from that used in this Form 10-QSB (8a, 2d, 2c,
6b, 6c, 6d-1, and 6f, respectively).

(2) Incorporated by reference from the Company's Registration Statement on Form
S-8 dated September 21, 2000, Commission File No. 333-46280.

(3) Incorporated by reference from the Company's Quarterly Report on Form 10-QSB
for the quarter ending June 30, 2002 filed August 8, 2002.


                                       11
<PAGE>


                                   SIGNATURES


In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                           Lark Technologies, Inc.
                                                (Registrant)



Date November 5, 2002                             /s/ Carl Balezentis
---------------------                      -------------------------------------
                                                      Carl Balezentis
                                           President and Chief Executive Officer


                                       12
<PAGE>


CERTIFICATION

I, Carl W. Balezentis, certify that:

I have reviewed this quarterly report on Form 10-QSB of Lark Technologies, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrant's internal controls; and


The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.


Date November 5, 2002                             /s/ Carl W. Balezentis
---------------------                      -------------------------------------
                                                      Carl W. Balezentis
                                           President and Chief Executive Officer


                                       13
<PAGE>

CERTIFICATION

I, Jon H. Luksich, certify that:

I have reviewed this quarterly report on Form 10-QSB of Lark Technologies, Inc.;

Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

Based on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this quarterly report;

The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrant's internal controls; and


The registrant's other certifying officers and I have indicated in this
quarterly report whether there were significant changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.


Date November 5, 2002                           /s/ Jon H. Luksich
---------------------                 ------------------------------------------
                                                    Jon H. Luksich
                                      Controller and principal financial officer


                                     14